Clinical Rheumatology

, Volume 31, Issue 4, pp 711–715 | Cite as

Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study

  • Luisa Costa
  • Francesco Caso
  • Lanfranco D’Elia
  • Mariangela Atteno
  • Rosario Peluso
  • Antonio Del Puente
  • Pasquale Strazzullo
  • Raffaele Scarpa
Brief Report

Abstract

The objective of the study was the evaluation of arterial stiffness, a cardiovascular risk factor, in patients with psoriatic arthritis (PsA). Twenty PsA patients classified on the basis of the CASPAR criteria (M/W, 14/6; mean age, 38.6 years; range, 22–53), attending our out-patient clinic, and 20 healthy control subjects (M/W, 14/6; mean age, 38.7 years; range, 22–53) matched for age, weight, height and with similar cardiometabolic profile entered the study. An exclusion criterion was the presence of known cardiovascular risk factors. Central hemodynamic parameters and aortic pulse wave velocity (aPWV) were assessed non-invasively by a SphygmoCor device. A significantly higher aPWV was recorded in PsA patients when compared to controls. The difference remained statistically significant after adjustment for age, weight, height, heart rate (HR) and central mean pressure (mean±SE; PsA, 8.3 ± 0.2 versus control, 6.8 ± 0.2 m/s; p < 0.0001). Among PsA patients, aPWV was related to known duration of disease (r = 0.63; p = 0.003). This result was confirmed after adjustment for the main confounders (β = 0.011; p = 0.013). These results support the concept of psoriatic disease as a systemic condition involving not only the skin, joints and gastrointestinal tract but also arterial vessels. The involvement of the vascular system indicates the presence of pathogenetic mechanisms that could accelerate the atherosclerotic process in this condition.

Keywords

Arterial stiffness Psoriatic arthritis Psoriatic disease Pulse wave velocity 

References

  1. 1.
    Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78PubMedCrossRefGoogle Scholar
  2. 2.
    Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33:210–212PubMedGoogle Scholar
  3. 3.
    Scarpa R, Altomare G, Marchesoni A, Balato N, Matucci Cerinic M, Lotti T, Olivieri I, Vena GA, Salvarani C, Valesini G, Giannetti A (2010) Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol 24:627–630PubMedCrossRefGoogle Scholar
  4. 4.
    Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103–1110PubMedCrossRefGoogle Scholar
  5. 5.
    Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA (2007) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57:1074–1080PubMedCrossRefGoogle Scholar
  6. 6.
    Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745PubMedCrossRefGoogle Scholar
  7. 7.
    Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N et al (2003) Premature coronary artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2407–2415PubMedCrossRefGoogle Scholar
  8. 8.
    Hunt BJ (2000) The endothelium in atherogenesis. Lupus 9:189–193PubMedCrossRefGoogle Scholar
  9. 9.
    Bachwich PR, Chensue SW, Larrick JW, Kunkel SL (1986) Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. Biochem Biophys Res Commun 136:94–101PubMedCrossRefGoogle Scholar
  10. 10.
    Philip R, Epstein LB (1986) Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 323:86–89PubMedCrossRefGoogle Scholar
  11. 11.
    De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK (1998) Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 329:653–657PubMedGoogle Scholar
  12. 12.
    Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126PubMedCrossRefGoogle Scholar
  13. 13.
    Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236–1241PubMedGoogle Scholar
  14. 14.
    Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J (2006) Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 113:664–670PubMedCrossRefGoogle Scholar
  15. 15.
    Nichols WW, O’Rourke M (1998) McDonald's blood flow in arteries: theoretical, experimental and clinical principles, 4th edn. Edward Arnold, London, pp 54–101Google Scholar
  16. 16.
    Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRefGoogle Scholar
  17. 17.
    Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M, Girolomoni G (2009) Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 218:110–113PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, The CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673PubMedCrossRefGoogle Scholar
  19. 19.
    Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H, European Network for Non-invasive Investigation of Large Arteries (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605PubMedCrossRefGoogle Scholar
  20. 20.
    Pauca AL, O’Rourke MF, Kon ND (2001) Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 38:932–937PubMedCrossRefGoogle Scholar
  21. 21.
    Anandarajah AP, Ritchlin CT (2004) Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 16:338–343PubMedCrossRefGoogle Scholar
  22. 22.
    Gokce N, Vita JA (2002) Clinical manifestations of endothelial dysfunction. In: Loscalzo J, Schafer A (eds) Thrombosis and hemorrhage. Lippincott Williams & Wilkins, Philadelphia, pp 685–706Google Scholar
  23. 23.
    Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF (2009) Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 68:868–872PubMedCrossRefGoogle Scholar
  24. 24.
    Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB (2007) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 56:831–839PubMedCrossRefGoogle Scholar
  25. 25.
    Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Béchir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Lüscher TF, Gay S, Ruschitzka F (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184–2187PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2011

Authors and Affiliations

  • Luisa Costa
    • 1
  • Francesco Caso
    • 1
  • Lanfranco D’Elia
    • 2
  • Mariangela Atteno
    • 1
  • Rosario Peluso
    • 1
  • Antonio Del Puente
    • 1
  • Pasquale Strazzullo
    • 2
  • Raffaele Scarpa
    • 1
  1. 1.Rheumatology Research Unit, Department of Clinical and Experimental MedicineUniversity Federico IINaplesItaly
  2. 2.Excellence Center of Hypertension, Department of Clinical and Experimental MedicineUniversity Federico IINaplesItaly

Personalised recommendations